FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaBusiness Wire • 11/16/23
Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference (Transcript)Seeking Alpha • 11/16/23
Nike, Merck Among 13 Companies To Announce Annual Dividend Increases In Second Half Of NovemberSeeking Alpha • 11/13/23
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?The Motley Fool • 11/11/23
Merck's drug Keytruda recommended for EU approval for biliary tract cancerProactive Investors • 11/10/23
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract CancerBusiness Wire • 11/10/23
Merck Foundation CEO and African First Ladies discussed Healthcare Capacity Building and Breaking Infertility Stigma at Africa Asia Luminary 2023Business Wire • 11/06/23
FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract CancerBusiness Wire • 11/01/23